Dr. Kapil Mehta

Dr. Kapil Mehta

Board Member

Dr. Mehta with more than 30 years of experience is an internationally recognized researcher for his scientific contributions. He is tenured Professor at a premier cancer institute- the University of Texas M. D. Anderson Cancer Center in Houston, Texas. 
Major area of research in his laboratory includes the use of liposomes as drug delivery system and understanding molecular mechanisms involved in inflammation-induced progression of cancer and other chronic diseases.

He has pioneered the identification of a novel inflammatory signaling pathway that promotes metastatic competence in epithelial cancer cells. Central to this pathway is aberrant expression of a stress-response gene (TGM2), whose expression is epigenetically regulated in multiple drug-resistant and metastatic tumors and is associated with poor disease outcome in cancer patients.

He holds 12 patents for various discoveries. Some formulations that he invented or co-invented are currently used in the clinic. Among these, Abelcet® is currently being marketed for treatment of fungal infections and Atragen® (for inducing long-term remissions in APL patients) and Lipo-Cur® (for treating pancreatic cancer) are undergoing clinical trials. He serves on Editorial Boards of several journals and has chaired or co-chaired many scientific meetings, including the prestigious Gordon Research Conference and FASEB Summer Conference. He has published more than 170 scientific articles, reviews, editorials, and book chapters in the area of his research. He has authored three books, including the most recent on ‘Chemoresistance in Cancer Cells’.

positions: Board Member
treatments: Infections and Atragen, Lipo-Cur, Long-Term Remissions in APL Patients, Treating Pancreatic Cancer
office: 28-29, Sector 18, Electronic City, Udyog Vihar, Gurgaon-122001, Haryana, India
workingdays: Sunday, Monday, Tuesday, Wednesday, Thursday, Friday, Saturday